Related Experiment Videos
Rifampin in the management of early prosthetic staphylococcus epidermidis endocarditis
The Annals of Thoracic Surgery
|January 1, 1980
Abstract:
Staphylococcus epidermidis endocarditis occurred four days following aortic valve replacement with a Björk-Shiley prosthesis. Antimicrobial therapy, shown to be effective by in vitro and in vivo studies, failed to eradicate the infection. When rifampin was added to the existing antibiotic regimen, peak serum bactericidal activity increased, the patient defervesced, and blood cultures became negative.
Insights
Staphylococcus epidermidis endocarditis after aortic valve replacement proved resistant to standard antibiotics. Adding rifampin to the treatment regimen successfully cleared the infection, indicated by negative blood cultures and patient recovery.
Area of Science:
- Cardiology
- Infectious Diseases
- Pharmacology
Background:
- Prosthetic valve endocarditis (PVE) is a serious complication following aortic valve replacement.
- Staphylococcus epidermidis is a common causative agent of PVE, often exhibiting antibiotic resistance.
Observation:
- A patient developed Staphylococcus epidermidis endocarditis four days post-aortic valve replacement with a Björk-Shiley prosthesis.
- Initial antimicrobial therapy, effective in vitro and in vivo, failed to resolve the infection.
Findings:
- Addition of rifampin to the existing antibiotic regimen significantly increased peak serum bactericidal activity.
- The patient experienced defervescence and achieved negative blood cultures after rifampin was added.
Implications:
- Rifampin may be a valuable adjunct in treating refractory Staphylococcus epidermidis prosthetic valve endocarditis.
- This case highlights the importance of reassessing and adjusting antibiotic strategies for resistant PVE.
- Further research into combination therapies for PVE is warranted.